Your session is about to expire
← Back to Search
Adjuvant Cemiplimab for Squamous Cell Carcinoma
Study Summary
This trial is testing if a drug called cemiplimab can help people with high-risk cutaneous squamous cell carcinoma (CSCC) live longer without their cancer coming back.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 608 Patients • NCT03257267Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the standard procedures for Cemiplimab patients?
"Cemiplimab is used to treat alk gene mutation and several other conditions, such as malignant neoplasms, metastatic cutaneous squamous cell carcinoma, and advance directives."
Are there other ongoing studies testing Cemiplimab's efficacy?
"At present, there are 60 Cemiplimab clinical trials underway. 4 of these trials are in their final stage of research (Phase 3). The majority of these studies are based in Barcelona and California; though, there are 1,819 locations worldwide conducting research for this medication."
Is this research being conducted simultaneously across different states?
"The primary locations for this study are Dana Farber/Harvard Cancer Center in Boston, Massachusetts, Sarah Cannon Research Institute - Tennessee Oncology in Nashville, Tennessee, and University of Pennsylvania in Basking Ridge, New jersey. However, there are 61 other sites where this trial is also taking place."
Has the FDA cleared cemiplimab for public use?
"Cemiplimab's safety is based on multiple rounds of data collection, with some efficacy data supporting it. Therefore, it received a score of 3."
How many people suffering from this condition can take part in this research?
"The pharmaceutical company sponsoring this clinical trial, Sanofi, needs a total of 412 eligible patients to participate. The study will be conducted across various sites, such as Dana Farber/Harvard Cancer Center in Boston, Massachusetts and Sarah Cannon Research Institute - Tennessee Oncology in Nashville, Tennessee."
Are there still empty slots where people can enroll in this clinical trial?
"The most recent update on clinicaltrials.gov shows that this trial is still enrolling patients. This clinical trial was posted on 6/4/2019."
Share this study with friends
Copy Link
Messenger